What is Travere Therapeutics, Inc.'s D&A?

Travere Therapeutics, Inc. (TVTX) reported D&A of $25.21M in Q1 2026.

How has Travere Therapeutics, Inc.'s D&A changed year-over-year?

Travere Therapeutics, Inc.'s D&A increased by 96.9% year-over-year, from $12.8M to $25.21M.

What is the long-term trend for Travere Therapeutics, Inc.'s D&A?

Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s D&A has grown at a 41.3% compound annual growth rate (CAGR), from $21.51M to $60.74M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Travere Therapeutics, Inc. TVTX D&A

D&A at other companies

Vertex PharmaceuticalsVRTX

$55.9M+15.5%

Vera TherapeuticsVERA

$140K+64.7%

LQD

Liquidia CorporationLQDA

$497K+10.2%

Ultragenyx PharmaceuticalRARE

$8M-11.1%

BridgeBio PharmaBBIO

$1.19M-7.6%

PTC TherapeuticsPTCT

$15.41M+113%

Other financials

Income statement

See full

Revenue$127.2M+55.6%

Gross profit$125.2M+62.5%

Operating income-$36.9M+13.5%

Net income-$37.1M+10.0%

EPS (diluted)-$0.40+14.9%

Balance sheet

See full

Cash & equivalents$78.4M+26.6%

Total debt$15.6M-82.6%

Total equity$98.7M+201%

Total assets$555.2M+1.2%

Cash flow

See full

Operating cash flow-$40.4M+4.3%

CapEx$140.0K—

Free cash flow-$42.5M+28.1%

Valuation

See full

Market cap$5.2B+72.3%

Profitability

See full

Gross margin98.6%+2.6pp

Operating margin-10.6%-5.0pp

Net margin-20.3%-9.5pp

FCF margin-133.9%-34.4pp

Returns & leverage

See full

Return on equity-706%-1,302pp

Debt / equity0.2×-2.6×

Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Travere Therapeutics, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Travere Therapeutics, Inc.'s D&A?: Travere Therapeutics, Inc. (TVTX) reported D&A of $25.21M in Q1 2026.
How has Travere Therapeutics, Inc.'s D&A changed year-over-year?: Travere Therapeutics, Inc.'s D&A increased by 96.9% year-over-year, from $12.8M to $25.21M.
What is the long-term trend for Travere Therapeutics, Inc.'s D&A?: Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s D&A has grown at a 41.3% compound annual growth rate (CAGR), from $21.51M to $60.74M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.